CoChat

Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer’s Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia

Open access
Shan, Chang, Zhang, Deng, Ma, Dong-ni, Hou, Yan-fang, Zhuang, Qian-qian, Gong, Yan-ling, Sun, Li-hao, Zhao, Hong-yan, Tao, Bei, Yang, Yu-ying, Li, Sheng-tian, Liu, Jian-min · 2023 · Cell Death Discovery

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by the accumulation of amyloid β peptides (Aβ) and impaired glucose metabolism in the brain. Osteocalcin (OCN), an osteoblast-derived protein, has been shown to modulate brain functions but whether it has any effect on AD is undetermined. In this study, daily intraperitoneal injection of OCN for 4 weeks ameliorated the anxiety-like behaviors and cognitive dysfunctions in the APP/PS1 transgenic AD mice model, as shown in the increased entries into the central area in open field test, the increased time and entries into open arms in elevated plus maze test, the increased time spent in the light chamber in light-dark transition test, as well as the reduced escape latency and the increased preference for target quadrant in Morris water maze test. Aβ burden in the hippocampus and cortex of AD mice was ameliorated by OCN. Besides, OCN improved the neural network function of the brain, mainly in the enhanced power of high gamma band in the medial prefrontal cortex of AD mice. The proliferation of astrocytes in the hippocampus in AD mice was also inhibited by OCN as demonstrated by immunofluorescence. Furthermore, OCN enhanced glycolysis in astrocytes and microglia, as evidenced by elevated glucose consumption, lactate production, and increased extracellular acidification rate. Such an effect was abolished when the receptor of OCN – Gpr158 was knockdown in astrocytes. Our study revealed OCN as a novel therapeutic factor for AD potentially through reducing Aβ burden and upregulation of glycolysis in neuroglia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41420-023-01343-y

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 OCN ameliorated the anxiety-like behaviors and cognitive dysfunctions in APP/PS1 transgenic AD mouse model. In the Open Field Test (A), OCN significantly increased the entries into the central area and total distance traveled in AD mice, especially in 1 μg/kg OCN group (n = 13–15 per group). In the Elevated Plus Maze Test (B), OCN increased the time and entries that AD mice entered into open arms, especially in the 1 μg/kg OCN group (n = 13–15 per group). In the Light-Dark Transition Test (C), OCN significantly increased the time of AD mice spent in the light chamber (n = 7–8 per group). In the Morris Water Maze Test (D), AD mice exhibited increased escape latency during the training stage, which was decreased by OCN treatment. In the probe test, 10 μg/kg OCN significantly increased the preference for target quadrant in AD mice (n = 12 per group). All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using LSD’s test or Kruskal–wallis test followed by post hoc comparisons using Dunn’s test for multiple groups’ comparisons. *P < 0.05, **P < 0.01.
Fig. 1 OCN ameliorated the anxiety-like behaviors and cognitive dysfunctions in APP/PS1 transgenic AD mouse model. In the Open Field Test (A), OCN significantly increased the entries into the central area and total distance traveled in AD mice, especially in 1 μg/kg OCN group (n = 13–15 per group). In the Elevated Plus Maze Test (B), OCN increased the time and entries that AD mice entered into open arms, especially in the 1 μg/kg OCN group (n = 13–15 per group). In the Light-Dark Transition Test (C), OCN significantly increased the time of AD mice spent in the light chamber (n = 7–8 per group). In the Morris Water Maze Test (D), AD mice exhibited increased escape latency during the training stage, which was decreased by OCN treatment. In the probe test, 10 μg/kg OCN significantly increased the preference for target quadrant in AD mice (n = 12 per group). All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using LSD’s test or Kruskal–wallis test followed by post hoc comparisons using Dunn’s test for multiple groups’ comparisons. *P < 0.05, **P < 0.01.CC BY · PubMed Central
Fig. 2 OCN reduced the Aβ burden in the hippocampus and cortex of AD mice. A–E Represent immunostaining showing Aβ burden in the hippocampus and cortex. (A) WT + NS; (B) WT + 10 μg/kg OCN; (C) AD + NS; (D) AD + 1 μg/kg OCN; (E) AD + 10 μg/kg OCN. F Quantitation of Aβ-positive area fraction (n = 4–5 per group). G Represent western blot showing Aβ and APP protein levels in hippocampus and cortex. H The quantitation of Aβ and APP protein levels in hippocampus and cortex (n = 3 per group). All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using Turkey’s test for multiple groups’ comparisons. *P < 0.05, **P < 0.01.
Fig. 2 OCN reduced the Aβ burden in the hippocampus and cortex of AD mice. A–E Represent immunostaining showing Aβ burden in the hippocampus and cortex. (A) WT + NS; (B) WT + 10 μg/kg OCN; (C) AD + NS; (D) AD + 1 μg/kg OCN; (E) AD + 10 μg/kg OCN. F Quantitation of Aβ-positive area fraction (n = 4–5 per group). G Represent western blot showing Aβ and APP protein levels in hippocampus and cortex. H The quantitation of Aβ and APP protein levels in hippocampus and cortex (n = 3 per group). All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using Turkey’s test for multiple groups’ comparisons. *P < 0.05, **P < 0.01.CC BY · PubMed Central
Fig. 3 OCN altered the LFP power in the mPFC. A 1 μg/kg OCN altered the LFP power at 0–200 Hz bands in AD mice, while 10 μg/kg OCN altered the LFP power in WT mice. B 1 μg/kg OCN increased the LFP power at High gamma (55–90 Hz) band both in WT and AD mice. Oscillations of High gamma band were higher in AD mice than WT mice after 1 μg/kg OCN treatment. C 1 μg/kg OCN did not affect the LFP power at Ripple band (100–200 Hz). D 10 μg/kg OCN did not affect the LFP power at High gamma band. E 10 μg/kg OCN increased the LFP power at Ripple band in WT mice. Oscillations of Ripple band were higher in WT mice than AD mice after 10 μg/kg OCN treatment. n = 5 per group. A P-value < 0.05 was considered to be statistically significant by paired t test when comparing the difference between before and after OCN treatment, unpaired t test when comparing the difference between WT group and AD group. **P < 0.01, ***P < 0.001.
Fig. 3 OCN altered the LFP power in the mPFC. A 1 μg/kg OCN altered the LFP power at 0–200 Hz bands in AD mice, while 10 μg/kg OCN altered the LFP power in WT mice. B 1 μg/kg OCN increased the LFP power at High gamma (55–90 Hz) band both in WT and AD mice. Oscillations of High gamma band were higher in AD mice than WT mice after 1 μg/kg OCN treatment. C 1 μg/kg OCN did not affect the LFP power at Ripple band (100–200 Hz). D 10 μg/kg OCN did not affect the LFP power at High gamma band. E 10 μg/kg OCN increased the LFP power at Ripple band in WT mice. Oscillations of Ripple band were higher in WT mice than AD mice after 10 μg/kg OCN treatment. n = 5 per group. A P-value < 0.05 was considered to be statistically significant by paired t test when comparing the difference between before and after OCN treatment, unpaired t test when comparing the difference between WT group and AD group. **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 4 OCN inhibited the proliferation of astrocytes in the hippocampus of AD mice, and Gpr158 is mainly co-localized with astrocytes in hippocampus. A Represent immunofluorescence showing GFAP in the hippocampus. B Represent immunofluorescence showing Iba-1 in the hippocampus. C Quantitation of relative GFAP-positive intensity in the hippocampus (n = 4–5 per group). D the quantitation of relative Iba-1-positive intensity in the hippocampus (n = 3–5 per group). E Relative mRNA expression of GFAP in the hippocampus (n = 3 per group). F Relative mRNA expression of Iba-1 in the hippocampus (n = 3 per group). G Gpr158 is co-localized with astrocytes in hippocampus. H Gpr158 is not mainly co-localized with microglia in hippocampus. All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using Turkey’s test for multiple groups’ comparisons. **P < 0.01, ***P < 0.001.
Fig. 4 OCN inhibited the proliferation of astrocytes in the hippocampus of AD mice, and Gpr158 is mainly co-localized with astrocytes in hippocampus. A Represent immunofluorescence showing GFAP in the hippocampus. B Represent immunofluorescence showing Iba-1 in the hippocampus. C Quantitation of relative GFAP-positive intensity in the hippocampus (n = 4–5 per group). D the quantitation of relative Iba-1-positive intensity in the hippocampus (n = 3–5 per group). E Relative mRNA expression of GFAP in the hippocampus (n = 3 per group). F Relative mRNA expression of Iba-1 in the hippocampus (n = 3 per group). G Gpr158 is co-localized with astrocytes in hippocampus. H Gpr158 is not mainly co-localized with microglia in hippocampus. All data represent the means ± SEM. A P-value < 0.05 was considered to be statistically significant by one-way ANOVA followed by post hoc comparisons using Turkey’s test for multiple groups’ comparisons. **P < 0.01, ***P < 0.001.CC BY · PubMed Central
Fig. 5 OCN enhanced glycolysis in astrocytes. A Glucose consumption (normalized to total protein) of C8D1A cells treated with vehicle or different concentrations of OCN. B Lactate production (normalized to total protein) of C8D1A cells treated with vehicle or different concentrations of OCN. C, D Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of C8D1A cells treated with vehicle or 100 ng/ml of OCN. Results are normalized to total protein. E qPCR analysis of mRNA levels of glycolytic enzymes of C8D1A cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of C8D1A cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).
Fig. 5 OCN enhanced glycolysis in astrocytes. A Glucose consumption (normalized to total protein) of C8D1A cells treated with vehicle or different concentrations of OCN. B Lactate production (normalized to total protein) of C8D1A cells treated with vehicle or different concentrations of OCN. C, D Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of C8D1A cells treated with vehicle or 100 ng/ml of OCN. Results are normalized to total protein. E qPCR analysis of mRNA levels of glycolytic enzymes of C8D1A cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of C8D1A cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).CC BY · PubMed Central
Fig. 6 OCN enhanced glycolysis in microglia. A Glucose consumption (normalized to total protein) of BV2 cells treated with vehicle or different concentrations of OCN. B Lactate production (normalized to total protein) of BV2 cells treated with vehicle or different concentrations of OCN. C, D Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of BV2 cells treated with vehicle or 100 ng/ml of OCN. Results are normalized to total protein. E qPCR analysis of mRNA levels of glycolytic enzymes of BV2 cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of BV2 cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).
Fig. 6 OCN enhanced glycolysis in microglia. A Glucose consumption (normalized to total protein) of BV2 cells treated with vehicle or different concentrations of OCN. B Lactate production (normalized to total protein) of BV2 cells treated with vehicle or different concentrations of OCN. C, D Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of BV2 cells treated with vehicle or 100 ng/ml of OCN. Results are normalized to total protein. E qPCR analysis of mRNA levels of glycolytic enzymes of BV2 cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of BV2 cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).CC BY · PubMed Central
Fig. 7 Ablation of GPR158 blocked the effect of OCN on glycolysis in astrocytes. A, B Protein levels of Gpr158 in control and Gpr158 knockdown C8D1A cells. C Glucose consumption (normalized to total protein) of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. D Lactate production (normalized to total protein) of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. E qPCR analysis of mRNA levels of glycolytic enzymes of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).
Fig. 7 Ablation of GPR158 blocked the effect of OCN on glycolysis in astrocytes. A, B Protein levels of Gpr158 in control and Gpr158 knockdown C8D1A cells. C Glucose consumption (normalized to total protein) of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. D Lactate production (normalized to total protein) of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. E qPCR analysis of mRNA levels of glycolytic enzymes of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. F, G Protein levels of glycolytic enzymes of control and Gpr158 knockdown C8D1A cells treated with vehicle or 100 ng/ml of OCN. (Data are presented as mean ± SD).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 57

Metadata

Authors
Shan, C., Zhang, D., Ma, D.-N., Hou, Y.-F., Zhuang, Q.-Q., Gong, Y.-L., Sun, L.-H., Zhao, H.-Y., Tao, B., Yang, Y.-Y., Li, S.-T., & Liu, J.-M.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Yang, Yu-ying
  • Li, Sheng-tian
Venue
Cell Death Discovery
Published
2023-02-06
Volume
9
Issue
1
Pages
46-46
ISSN
2058-7716 (ISSN-L)
OpenAlex
W4319298595
Cited by
53
References
61
Citations by year
2026: 14 · 2025: 25 · 2024: 13 · 2023: 1
FWCI
9.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death Discovery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (No.81871064)
  • Shanghai Science and Technology Development Foundation (13dz2260500)
  • Natural Science Foundation of Shanghai (21ZR1430400)
  • Shanghai Municipal Education Commission (2019-01-07-00-02-E00037)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
osteocalcin, Alzheimer's disease, amyloid-beta, cognitive impairment, anxiety-like behavior, APP/PS1 mice, astrocytes, microglia, glycolysis, glucose metabolism, GPR158, hippocampus, medial prefrontal cortex, high gamma band, lactic acid production, extracellular acidification rate, glial cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer’s Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia. https://app.cochat.ai/papers/10.1038/s41420-023-01343-y
The paper
Shan, C., Zhang, D., Ma, D.-N., Hou, Y.-F., Zhuang, Q.-Q., Gong, Y.-L., Sun, L.-H., Zhao, H.-Y., Tao, B., Yang, Y.-Y., Li, S.-T., & Liu, J.-M. (2023). Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer’s Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01343-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.